title: Langerhans-cell histiocytosis--excellent response to etoposide.
abstract: We describe an adult with progressive LCH who received oral etoposide as primary treatment. The response is documented and the strategical implications of this drug in Langerhans-cell histiocytosis discussed. Langerhans-cell histiocytosis (LCH) is the term recognized since 1987 for the group of diseases previously designated histiocytosis X. It is not now regarded as a malignant neoplastic process and there is some evidence to suggest that it is due to abnormal immunity, but cytotoxic drugs and steroids are still the mainstay of systemic treatment. Etoposide (VP16) is a semisynthetic epipodophyllotoxin derivative effective in the treatment of malignancies of the monocyte-macrophage lineage and used in resistant or relapsed childhood LCH. There are no previous reports of its use as firstline monotherapy in adults with LCH.
authors.affiliation: Department of Dermatology, St Bartholomew's Hospital, London, UK.
authors.forename: S C
authors.initials: SC
authors.lastname: Mayou
authors.forename: A C
authors.initials: AC
authors.lastname: Chu
authors.forename: D D
authors.initials: DD
authors.lastname: Munro
authors.forename: N
authors.initials: N
authors.lastname: Plowman
mesh_terms: D000328:Adult; D005047:Etoposide / Q000627:therapeutic use*; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D012867:Skin / Q000473:pathology
chemical_list: D005047:Etoposide